Lund, Sweden – March 10, 2026
Alligator Bioscience, a clinical-stage biotechnology company focused on tumor-directed immuno-oncology therapies, has announced that the United States Patent and Trademark Office (USPTO) has granted a key patent protecting its proprietary bispecific antibody technology platform. The newly granted intellectual property strengthens the company’s strategic position in the rapidly expanding field of bispecific antibody engineering, providing protection for a tetravalent antibody format designed to bind two different antigens simultaneously. The technology underpins several of the company’s drug development programs and supports its long-term strategy to develop next-generation immunotherapies targeting multiple cancer pathways at the same time.
Patent Strengthens Next-Generation Antibody Engineering
The newly granted patent protects the structural architecture of Alligator Bioscience’s tetravalent bispecific antibody format, a design engineered to enable stable and efficient assembly of antibodies capable of dual antigen binding. This innovation represents an important advancement in antibody-based drug development, as it enables therapeutic molecules to target two different biological pathways simultaneously, enhancing the ability of immunotherapies to activate the immune system against cancer cells.
Bispecific antibodies are emerging as one of the most promising approaches in modern oncology drug development, offering the ability to simultaneously engage immune cells and tumor cells to trigger a more effective anti-tumor immune response. Alligator’s patented antibody structure is designed to provide greater stability, improved functionality, and increased therapeutic flexibility, enabling researchers to create antibody drugs capable of addressing complex tumor biology.
The platform allows researchers to combine targets such as immune modulators and tumor-associated antigens, creating therapeutic candidates that can potentially overcome resistance mechanisms commonly seen with conventional single-target antibody treatments. This dual-target approach is expected to play a key role in the development of more powerful immuno-oncology therapies.
Advertisement
Expanding Pipeline of Tumor-Directed Immunotherapies
The bispecific antibody technology protected by the patent forms the foundation of multiple research and development programs within Alligator Bioscience’s oncology pipeline. The platform supports the company’s strategy of developing tumor-directed antibody therapies that activate immune responses while reversing the immunosuppressive environment commonly found within tumors.
One of the most advanced programs within the company’s pipeline is mitazalimab, a CD40 agonist antibody designed to stimulate immune activation in cancer patients. The therapy has shown promising clinical results and is currently preparing to enter Phase 3 development following encouraging survival data in metastatic pancreatic cancer patients from the Phase 2 OPTIMIZE-1 clinical trial.
By strengthening intellectual property protection around its antibody platform, Alligator Bioscience aims to secure long-term exclusivity for its proprietary technologies while accelerating the development of new oncology therapies. Strong patent protection is critical in the biotechnology sector because it ensures that companies can protect innovative drug platforms, attract strategic partnerships, and support long-term research investment.
Strategic Value for Partnerships and Commercial Growth
The new patent also strengthens Alligator’s ability to form strategic collaborations with pharmaceutical and biotechnology partners interested in developing antibody-based therapies. In 2025, the company entered into an evaluation and option agreement involving its RUBY™ antibody format, demonstrating the growing commercial interest in its antibody engineering technologies.
Technology platforms such as bispecific antibodies are increasingly attractive to pharmaceutical companies because they offer versatile frameworks for developing multiple drug candidates across different disease indications. By licensing or partnering around these technologies, biotechnology firms can expand their development pipelines while sharing expertise and resources with larger industry partners.
The granting of the patent therefore represents more than just intellectual property protection; it also strengthens the company’s competitive position in the global immuno-oncology market, where innovative antibody platforms are becoming central to the development of next-generation cancer therapies.
As cancer research continues to evolve, bispecific antibodies are expected to play a transformative role in oncology, enabling scientists to design therapies capable of simultaneously targeting tumors and activating immune responses with greater precision. By securing strong patent protection around its platform technology, Alligator Bioscience is positioning itself to advance cutting-edge antibody therapies while building long-term scientific and commercial value in the rapidly growing field of immuno-oncology.
z
Source: Alligator Bioscience press release
